Abstract-Organizations are often faced with the challenge of providing data management solutions for large, heterogenous datasets that may have different underlying data and programming models. For example, a medical dataset may have unstructured text, relational data, time series waveforms and imagery. Trying to fit such datasets in a single data management system can have adverse performance and efficiency effects. As a part of the Intel Science and Technology Center on Big Data, we are developing a polystore system designed for such problems. BigDAWG (short for the Big Data Analytics Working Group) is a polystore system designed to work on complex problems that naturally span across different processing or storage engines. BigDAWG provides an architecture that supports diverse database systems working with different data models, support for the competing notions of location transparency and semantic completeness via islands and a middleware that provides a uniform multi-island interface. Initial results from a prototype of the BigDAWG system applied to a medical dataset validate polystore concepts. In this article, we will describe polystore databases, the current BigDAWG architecture and its application on the MIMIC II medical dataset, initial performance results and our future development plans.

No abstract

OBJECTIVE To investigate whether the use of a belladonna and opium (B&O) rectal suppository administered immediately before ureteroscopy (URS) and stent placement could reduce stent-related discomfort. METHODS A randomized, double-blinded, placebo-controlled study was performed from August 2013 to December 2014. Seventy-one subjects were enrolled and randomized to receive a B&O (15 mg/30 mg) or a placebo suppository after induction of general anesthesia immediately before URS and stent placement. Baseline urinary symptoms were assessed using the American Urological Association Symptom Score (AUASS). The Ureteral Stent Symptom Questionnaire and AUASS were completed on postoperative days (POD) 1, 3, and after stent removal. Analgesic use intra-operatively, in the recovery unit, and at home was recorded. RESULTS Of the 71 subjects, 65 had treatment for ureteral (41%) and renal (61%) calculi, 4 for renal urothelial carcinoma, and 2 were excluded for no stent placed. By POD3, the B&O group reported a higher mean global quality of life (QOL) score (P = .04), a better mean quality of work score (P = .05), and less pain with urination (P = .03). The B&O group reported an improved AUASS QOL when comparing POD1 with post-stent removal (P = .04). There was no difference in analgesic use among groups (P = .67). There were no episodes of urinary retention. Age was associated with unplanned emergency visits (P <.00) and “high-pain” measure (P = .02) CONCLUSION B&O suppository administered preoperatively improved QOL measures and reduced urinary-related pain after URS with stent. Younger age was associated with severe stent pain and unplanned hospital visits.

No abstract

No abstract